Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: SU16f inhibits fibrotic scar formation and facilitates axon regeneration and locomotor function recovery after spinal cord injury by blocking the PDGFRβ pathway

Fig. 5

In situ injection of PDGFB or PDGFD induces fibrosis in uninjured spinal cord. A–L Immunofluorescence staining of PDGFB (red) and PDGFRβ (green) in sagittal and coronal sections of the Control and PDGFB groups at 7 days after injection. M–X Immunofluorescence staining of PDGFD (red) and PDGFRβ (green) in sagittal and coronal sections of the Control and PDGFD groups at 7 days after injection. Y–D’ Immunofluorescence staining of PDGFRβ (green), fibronectin (red) and laminin (violet) in sagittal sections of the PDGFB and PDGFB + SU16f groups at 7 days after injection. E’–J’ Immunofluorescence staining of PDGFRβ (green), fibronectin (red) and laminin (violet) in sagittal sections of the PDGFD and PDGFD + SU16f groups at 7 days after injection. Arrowheads indicate the sites of in situ injection. Scale bars: 200 μm

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094